Palantir Levels to Watch After Post-Earnings Surge<\/p>\n
9 hr 15 min ago<\/p>\n
Palantir Technologies (PLTR<\/a>) shares\u00a0jumped Tuesday after the data analytics software provider raised its full-year outlook amid booming demand for its AI platform.\u00a0\n<\/p>\n The company\u00a0posted quarterly revenue that surpassed $1 billion for the first time<\/a>, topping Wall Street estimates, and now expects full-year revenue of between $4.14 billion and $4.15 billion, up from $3.89 to $3.9 billion\u00a0previously<\/a>. \u00a0CEO Alex Karp said Palantir’s commercial business nearly doubled from a year earlier, while its U.S. business grew 68%, which he attributed to “the astonishing impact of AI leverage.”\n<\/p>\n Following the company\u2019s blowout results, investment banks Bank of America, Morgan Stanley, and Deutsche Bank\u00a0raised their price targets on Palantir shares<\/a>. The stock rose nearly 8% to $173 on Tuesday and has gained about 600% over the past year. The stock has been boosted by the company\u2019s\u00a0increasing business with the federal government<\/a>\u00a0and surging enterprise demand for its AI-powered tools.\u00a0\n<\/p>\n Source: TradingView,com.<\/p>\n Palantir shares broke out above the top trendline of a\u00a0rising wedge<\/a>\u00a0in Tuesday\u2019s trading session. While this chart pattern often signals a potential trend reversal, a bullish\u00a0breakout<\/a>\u00a0indicates strong price momentum\n<\/p>\n Moreover, the\u00a0relative strength index\u00a0<\/a>confirms bullish\u00a0price action<\/a>, though it also flashes\u00a0overbought<\/a>\u00a0conditions, increasing the likelihood of near-term profit taking.\n<\/p>\n The measured move technique projects an upside price target of $201.30. Investors should also watch crucial support levels on Palantir’s chart around $148, $125 and $98.\n<\/p>\n Read the full technical analysis piece here<\/a>.\n<\/p>\n –Timothy Smith<\/a>\n<\/p>\n Biggest S&P 500 Movers on Tuesday<\/p>\n 10 hr 19 min ago<\/p>\n Decliners\n<\/p>\n Shares of the technology-focused research and advisory firm Gartner (IT<\/a>) logged the S&P 500’s weakest performance on Tuesday, plummeting nearly 28%. Although second-quarter revenue and adjusted earnings per share topped estimates, Gartner reduced its full-year sales guidance, and its updated revenue outlook fell short of consensus expectations. The company cited soft demand within its insights segment\u2014Gartner’s largest research unit accounting for more than half of sales\u2014as businesses moderate spending in response to the uncertain economic environment. Advancers\n<\/p>\n Axon Enterprise (AXON<\/a>) shares jumped more than 16%, rising the most of any S&P 500 stock, after the maker of the Taser and other law enforcement gear surpassed sales and profit estimates for the second quarter and lifted its full-year outlook. Strong growth in annual recurring revenue suggested that Axon is gaining momentum in its software business, and the firm has seen strong demand for its generative artificial intelligence products, including a tool that drafts an initial police report based on camera footage. –Michael Bromberg<\/a>\n<\/p>\n AMD Shares Fall After Hours Despite Strong Revenue, Outlook<\/p>\n 10 hr 35 min ago<\/p>\n Advanced Micro Devices (AMD<\/a>) reported second-quarter revenue and issued current-quarter guidance above analysts’ projections Tuesday, but shares slipped in after-hours trading.\n<\/p>\n The Santa Clara, Calif.-based firm posted revenue that jumped 32% year-over-year to a record $7.67 billion, well above the $7.43 billion consensus estimate of analysts polled by Visible Alpha. Adjusted earnings per share of $0.48 matched expectations.\n<\/p>\n Data Center unit revenue climbed 14% to $3.2 billion, slightly below expectations of $3.32 billion. Client revenue soared 67% to a record $2.5 billion and Gaming revenue surged 73% to $1.1 billion, with the former matching and the latter well above estimates. Embedded segment revenue fell 4% to $824 million, a tick below projections.\n<\/p>\n “We delivered strong revenue growth in the second quarter led by record server and PC processor sales,” CEO Lisa Su said. “We are seeing robust demand\u00a0 across our computing and AI product portfolio and are well positioned to deliver significant growth in the second half of the year.”\n<\/p>\n CEO Lisa Su at the AI Action Summit in Paris earlier this year.<\/p>\n Nathan Laine \/ Bloomberg \/ Getty Images<\/p>\n Gross margin was 43% but AMD said it would have been 54% had it not been “impacted by the U.S. Government’s export control on our AMD Instinct MI308 data center GPU products,” which amounted to a roughly $800 million hit. AMD had warned in May that it would take charges from tighter restrictions on chip exports to China, though it said last month that it\u00a0planned to restart exports<\/a>\u00a0of its MI308 chips once it received final approval from U.S. authorities.\n<\/p>\n For the current quarter, AMD sees revenue between $8.4 billion and $9.0 billion, above Visible Alpha consensus of $8.28 billion. The outlook does not include any revenue from MI308 shipments to China.\n<\/p>\n Shares initially rose in after-hours trading following the report before reversing course, and recently were down more than 2%. They ended Tuesday’s regular session at $174.31, up nearly 45% this year.\n<\/p>\n –Aaron Rennie<\/a>\n<\/p>\n TASER Maker Axon Soars on Earnings, Outlook<\/p>\n 11 hr 47 min ago<\/p>\n Axon Enterprise (AXON<\/a>) shares soared Tuesday after the public safety technology company reported better-than-expected results and issued a rosy outlook.\n<\/p>\n The stock jumped 16% to an all-time high, pacing\u00a0S&P 500<\/a>\u00a0advancers today. Axon shares have risen 46% since the start of the year, far outpacing the benchmark index’s 7% gain over the period.\n<\/p>\n The Scottsdale, Arizona-based company reported adjusted earnings per share of $2.12 on revenue that increased 33%\u00a0year-over-year<\/a>\u2014its 14th consecutive quarter with a gain above 25%\u2014to $668.5 million. Analysts polled by Visible Alpha had expected $1.44 and $641.0 million, respectively.\n<\/p>\n Software & Services revenue surged 39% to\u00a0$292 million, paced “by growing adoption of premium digital evidence management solutions, real-time operations, virtual reality training and productivity tools,” Axon said. Connected Devices revenue rose 29% to\u00a0$376 million, “driven by demand for TASER 10.”\n<\/p>\n A police officer demonstrates a TASER 10 in Germany.<\/p>\n Michael Kappeler \/ Picture Alliance \/ Getty Images)<\/p>\n Axon lifted its full-year revenue outlook to between $2.65 billion and $2.73 billion from the prior range of $2.60 billion\u00a0to\u00a0$2.70 billion. It also raised its 2025\u00a0adjusted EBITDA<\/a>\u00a0forecast to between\u00a0$665 million\u00a0and\u00a0$685 million from\u00a0$650 million\u00a0to\u00a0$675 million.\n<\/p>\n “Artificial intelligence, drones and robotics, real-time operations, cameras, and our newest TASER devices and virtual reality,\u00a0each of those are resonating across our\u00a0customer<\/a>\u00a0base,” Axon founder and CEO Rick Smith said on the earnings call late Monday, according to a transcript provided by AlphaSense.\u00a0“There’s no one breakout product driving conversations.\u00a0It’s everything.”\n<\/p>\n –Aaron Rennie<\/a>\n<\/p>\n Peter Thiel-Backed Bullish Targets IPO Valuation of $4 Billion<\/p>\n 13 hr 16 min ago<\/p>\n Bullish, the cryptocurrency exchange backed by billionaire Peter Thiel, said it would be seeking a valuation of more than $4 billion in an\u00a0initial public offering<\/a>.\n<\/p>\n In a regulatory filing Monday, the company said it would be offering for sale 20.3 million shares at a price range of $28 to $31 each, or as much as $629.3 million. In addition, the underwriters have 30 days from the publication of the prospectus to purchase another 3.045 million shares. Bullish added that it planned to initiate the IPO “as soon as practicable after this Registration Statement becomes effective.”\n<\/p>\n It noted that BlackRock (BLK<\/a>) and Cathie Wood’s ARK Investment Management have already agreed to purchase a total of $200 million worth of shares.\u00a0\n<\/p>\n Ark Investment CEO Cathie Wood speaking at an event in June.<\/p>\n Chris Ratcliffe \/ Bloomberg \/ Getty Images<\/p>\n Bullish said it has applied to list on the\u00a0New York Stock Exchange<\/a>\u00a0under the ticker symbol “BLSH.”\n<\/p>\n In its prospectus, the company reported its first-quarter trading volume grew 78% from 2024, and it had an average daily volume of $2.55 billion. Bullish also owns the CoinDesk crypto media site.\u00a0\n<\/p>\n CEO Tom Farley said that “the digital assets industry is at the inflection point of institutional adoption and Bullish is uniquely positioned at the center of this market.”\n<\/p>\n –Bill McColl<\/a>\n<\/p>\n DuPont Rises on Earnings Beat, Rosy Outlook<\/p>\n 14 hr 51 min ago<\/p>\n DuPont (DD<\/a>) shares rose Tuesday after the chemicals and materials manufacturer posted better-than-expected results and boosted its guidance on higher sales and volumes, plus a tax benefit. It also lowered its anticipated tariff hit.\n<\/p>\n The Delaware-based company reported second-quarter adjusted\u00a0earnings per share (EPS)\u00a0<\/a>of $1.12 on revenue that increased 3% year-over-year to $3.26 billion. Analysts surveyed by Visible Alpha had expected $1.06 and $3.24 billion, respectively.\n<\/p>\n ElectronicsCo unit revenue increased 6% to $1.17 billion, driven by demand for\u00a0artificial intelligence<\/a>\u00a0technology applications. Revenue at the IndustrialsCo segment was up 1% to $2.09 billion on growth in Healthcare & Water Technologies sales.\u00a0\n<\/p>\n CEO Lori Koch said that as a result of the strong performance, DuPont was increasing its full-year outlook, which incorporates a new analysis tariffs. CFO Antonella Franzen said the company now sees 2025 adjusted EPS of approximately $4.40, with an impact of $0.04 per share from what it believes will be a $20 million headwind from tariffs. In the\u00a0first quarter<\/a>, Franzen predicted tariff costs of $60 million, with a $0.10 drag on adjusted EPS of $4.30 to $4.40.2\n<\/p>\n Koch added that the company is on track to complete its planned\u00a0spinoff\u00a0<\/a>of its electronics business on Nov. 1.\u00a0\n<\/p>\n Even with today’s near-4% gain, DuPont shares remain in negative territory for the year.\n<\/p>\n DuPont shares are down about 3.5% since the start of the year, lagging the performance of the benchmark S&P 500 index in 2025.<\/p>\n TradingView<\/p>\n –Bill McColl<\/a>\n<\/p>\n Wall Street Even More Bullish on Palantir After Earnings<\/p>\n 16 hr 3 min ago<\/p>\n Palantir Technologies (PLTR<\/a>) shares show no signs of slowing down, with several Wall Street analysts increasing their price targets after the company’s strong earnings report.\n<\/p>\n Bank of America analysts noted that Palantir’s quarterly revenue rose 48% year-over-year to top $1 billion for the first time, and with margins of 46%, the firm’s “Rule of 40” score was 94%.\u00a0As a result, they affirmed their “buy” rating on the stock and raised their price objective to $180 from $150, “mainly to reflect stronger growth and profitability.”\n<\/p>\n Morgan Stanley raised its Palantir price target to $155 from $88, noting its “significant margin expansion” and calling the company a “clear AI winner.”\n<\/p>\n \u00a0Meanwhile, Deutsche Bank analysts increased their rating on the stock to “hold” from “sell,” and doubled their price target to $160 from $80.\n<\/p>\n Palantir shares were up nearly 7% at around $171 in midday trading, after hitting a record high of $176 this morning.\n<\/p>\n –Aaron Rennie<\/a>\n<\/p>\n Vertex Dives After Disappointing Pain Medicine Trial<\/p>\n 17 hr 25 min ago<\/p>\n Shares of Vertex Pharmaceuticals (VRTX<\/a>) sank Tuesday, a day after the drugmaker announced a study showed its experimental pain medicine was not successful, and it would no longer move forward with its development.\n<\/p>\n The company said a\u00a0Phase 2 trial<\/a>\u00a0of VX-993 “did not result in a statistically significant improvement on the primary endpoint of the time-weighted Sum of the Pain Intensity Difference from 0 to 48 hours (SPID48) compared to placebo.”\n<\/p>\n Chief Medical Officer Dr. Carmen Bozic said that the findings, along with other data on VX-993, indicated that the treatment was not expected to be superior to Vertex’s other NaV1.8 inhibitors, so “we will not be advancing it as monotherapy in acute pain.” The company was testing VX-993 as a follow-up to its NaV1.8 inhibitor drug, Journavx, which received\u00a0Food and Drug Administration (FDA)<\/a>\u00a0approval in January.\n<\/p>\n The news offset Vertex’s better-than-expected second-quarter results. The company posted adjusted earnings per share of $4.52, with revenue rising 12% year-over-year to $2.96 billion. Both exceeded estimates of analysts surveyed by Visible Alpha.\u00a0Most of its sales ($2.55 billion) came from its Cystic Fibrosis treatment known in the U.S. as Trikafta.\n<\/p>\n Vertez shares were down 17% in recent trading, pushing the stock into negative territory for 2025.\n<\/p>\n –Bill McColl<\/a>\n<\/p>\n Palantir Soars on AI-Fueled Earnings Beat, Boosted Outlook<\/p>\n 18 hr 19 min ago<\/p>\n Palantir (PLTR<\/a>) shares soared in early trading Tuesday after the company reported second-quarter earnings that topped analysts’ expectations and raised its outlook on strong demand for its AI Platform.\n<\/p>\n The data analytics software company reported adjusted earnings of 16 cents on revenue that jumped 48% year-over-year to a record $1 billion, above Wall Street estimates.\u00a0\n<\/p>\n CEO Alex Karp called it a “phenomenal quarter” that underlined “the astonishing impact of AI leverage.”\n<\/p>\n CEO Alex Karp at an event last month.<\/p>\n Andrew Caballero-Reynolds \/ AFP \/ Getty Images<\/p>\n The CEO said Palantir’s commercial business nearly doubled from a year ago, while its U.S. business grew 68%.\n<\/p>\n Looking ahead, Palantir said it sees third-quarter sales of $1.08 billion to $1.09 billion, and full-year revenue of $4.14 billion to $4.15 billion, up from $3.89 to $3.9 billion\u00a0previously<\/a>. Both ranges were well above analysts’ estimates compiled by Visible Alpha.\n<\/p>\n Palantir shares hit a record high this morning and were up 9% in recent trading. The stock has gained 130% since the start of 2025.\n<\/p>\n –Kara Greenberg<\/a>\n<\/p>\n How Much AMD is Expected to Move After Earnings<\/p>\n 19 hr 28 min ago<\/p>\n Advanced Micro Devices (AMD<\/a>) is set to report second-quarter results after the closing bell on Tuesday, with traders anticipating a sizable move from the chipmaker’s stock.\n<\/p>\n Current options pricing suggests traders expect the stock could move more than 7% by the end of this week, from Monday’s close near $177. A move of that scale on the high side would push the stock just over $190, nearing its record in March of last year. At the low end, the stock could drop to about $163. The shares have gained more than 45% in 2025 so far.\n<\/p>\n AMD shares have significantly outperformed the gains of the benchmark S&P 500 and AI chip giant Nvidia so far this year.<\/p>\n TradingView<\/p>\n AMD shares rose close to 2% the day after the company’s first-quarter report, while they fell 6% and 10%, respectively, the days after the two previous reports.\u00a0In May<\/a>, the company beat estimates and gave a revenue forecast with a midpoint above the analyst consensus.\n<\/p>\n The chipmaker is widely expected to report rising sales, but falling profits for the second quarter, after AMD warned in May that it would likely take a hit from tighter restrictions on chip exports to China.\n<\/p>\n Wall Street analysts surveyed by Visible Alpha are divided on the stock, but lean more bullish than bearish, after AMD reportedly said it\u00a0plans to resume exports<\/a>\u00a0of its MI308 chips to China, once authorized by U.S. authorities.\n<\/p>\n AMD shares were up 1% in recent premarket trading.\n<\/p>\n
\nVertex Pharmaceuticals (VRTX<\/a>)\u00a0shares dropped 21%. Despite beating top- and bottom-line estimates with its second-quarter results, boosted by sales growth from its treatment for cystic fibrosis,\u00a0the biopharmaceutical company announced<\/a>\u00a0it would halt development on an experimental next-generation pain treatment that failed to reach its primary endpoint in a recent Phase 2 trial.
\nTransDigm Group (TDG<\/a>), a supplier of engineered aircraft components, missed sales and profit estimates for its fiscal third quarter. A disappointing performance from TransDigm’s commercial original equipment manufacturing segment, which the company attributed to inventory destocking and sluggish build rates,\u00a0weighed on the results. TransDigm shares tumbled 12%.<\/p>\n
\nAI software giant Palantir Technologies (PLTR<\/a>) also\u00a0increased its 2025 outlook<\/a>\u00a0after topping second-quarter sales and profit estimates, highlighting strong demand for its Artificial Intelligence Platform as a key contributor to a record $1 billion in quarterly revenue. Following the strong results, analysts at Bank of America, Morgan Stanley, and Deutsche Bank\u00a0raised their price targets<\/a>\u00a0on Palantir stock. Shares of the data analytics company surged 7.8%.
\nShares Leidos Holdings (LDOS<\/a>) jumped 7.5% in the wake of the aerospace and defense contractor’s quarterly earnings release. Adjusted EPS came in well ahead of expectations, while revenue edged out forecasts. Leidos noted an uptick in demand across its customer segments, with particular strength in its defense systems unit as geopolitical tensions remain elevated. Advances in the areas of AI and maritime autonomy also helped underpin the strong performance.<\/p>\n